Sartorius AG Stock
Stocks
SRT3
DE0007165631
Advanced Medical Equipment & Technology
OTC Markets Traded|
Real-time Estimate
Tradegate
08:02:27 2026-10-15 EDT
|
5-day change | 1st Jan Change | ||
| 256.80 EUR | -0.47% |
|
+4.46% | +4.33% |
| 10-12 | Sartorius AG : JP Morgan maintains a Buy rating | ZD |
| 10-08 | AlphaValue's positive view is not enough for Sartorius Stedim Biotech |  |
| Market Cap | 16.01B 17.81B 14.95B 13.55B 25.43B 1,695B 25.59B 179B 70.03B 880B 66.87B 65.43B 2,829B | P/E 2026 * |
69.5x | P/E 2027 * | 53.4x |
|---|---|---|---|---|---|
| Enterprise Value | 19.59B 21.79B 18.29B 16.57B 31.11B 2,074B 31.31B 219B 85.69B 1,076B 81.82B 80.05B 3,462B | EV / Sales 2026 * |
5.28x | EV / Sales 2027 * | 4.73x |
| Free-Float |
35.87% | Yield 2026 * |
0.31% | Yield 2027 * | 0.37% |
| Markets | Quality | ||
|---|---|---|---|
Xetra
| SRT3 | Delayed | |
CBOE
| SRT3d | Real-time | |
|
Tradegate
| SRT3 | Real-time | |
|
Boerse Muenchen
| SRT3 | Real-time | |
|
Wiener Boerse
| SRT3 | End-of-day quote | |
|
OTC Markets
| SUVPF | Delayed | |
|
Börse Stuttgart
| SRT3 | Delayed | |
|
Deutsche Boerse AG
| SRT3 | Delayed | |
|
London S.E.
| 0NIR | Delayed | |
|
CBOE
| 0NIR | Real-time | |
|
Swiss Exchange
| SRT3 | Delayed | |
|
Borsa Italiana
| 1SRT3 | End-of-day quote |
Last Transcript: Sartorius AG
| 1 day | -0.47% | ||
| 1 week | +4.46% | ||
| Current month | -0.58% | ||
| 1 month | +8.09% | ||
| 3 months | +4.24% | ||
| 6 months | +11.55% | ||
| Current year | +4.33% |
| 1 week | 249.4 |  | 262.3 |
| 1 month | 236.3 | | 271.9 |
| Current year | 198.5 | | 271.9 |
| 1 year | 198.5 | | 271.9 |
| 3 years | 166.05 | | 383.7 |
| 5 years | 166.05 | | 631.6 |
| 10 years | 63.65 | | 631.6 |
| Manager | Title | Age | Since |
|---|---|---|---|
Michael Grosse
CEO | Chief Executive Officer | 59 | 2025-06-29 |
Florian Funck
DFI | Director of Finance/CFO | 55 | 2024-03-31 |
Volker Niebel
COO | Chief Operating Officer | 70 | 2000-12-31 |
| Director | Title | Age | Since |
|---|---|---|---|
Annette Becker
BRD | Director/Board Member | 62 | 2002-08-31 |
Lothar Kappich
CHM | Chairman | 69 | 2017-07-18 |
| Director/Board Member | 77 | 2011-11-28 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 5/1/26 | Free | Executive/Senior Manager | 4,268 | 0.0114% | ||
| 5/1/26 | Free | Executive/Senior Manager | 5,203 | 0.0139% | ||
| 3/12/26 | Buy | Chairman | 191 | 0.0005% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.47% | +4.46% | +21.48% | -4.41% | 17.81B | |
| +1.53% | +1.68% | +28.03% | +39.42% | 249B | |
| +0.83% | +2.84% | +8.99% | +7.29% | 158B | |
| -0.43% | +1.38% | -3.70% | +53.85% | 148B | |
| -0.72% | +3.42% | -55.32% | -13.17% | 62.32B | |
| +0.34% | +4.99% | -14.75% | -15.73% | 49.61B | |
| +1.38% | +0.78% | +17.84% | +22.14% | 49.83B | |
| -1.42% | +5.26% | +3.37% | +37.59% | 48.14B | |
| +1.40% | +2.90% | +26.05% | +57.45% | 49.06B | |
| +1.73% | +0.14% | +31.06% | +72.84% | 42.9B | |
| Average | +0.94% | +1.90% | +6.31% | +25.73% | 87.5B | |
| Weighted average by Cap. | +0.90% | +1.89% | +8.81% | +29.87% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 3.71B 4.13B 3.46B 3.14B 5.89B 393B 5.93B 41.56B 16.23B 204B 15.5B 15.16B 656B | 4.08B 4.54B 3.81B 3.45B 6.48B 432B 6.52B 45.71B 17.85B 224B 17.04B 16.67B 721B |
| Net income | 248M 276M 232M 210M 394M 26.29B 397M 2.78B 1.09B 13.65B 1.04B 1.01B 43.89B | 318M 354M 297M 269M 505M 33.68B 508M 3.56B 1.39B 17.48B 1.33B 1.3B 56.23B |
| Net Debt | 3.58B 3.98B 3.34B 3.03B 5.68B 379B 5.72B 40.09B 15.65B 197B 14.95B 14.62B 632B | 3.29B 3.66B 3.07B 2.78B 5.22B 348B 5.25B 36.82B 14.38B 181B 13.73B 13.43B 581B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-10-15 | €257.90 | -0.04% | 20,239 |
| 26-10-14 | €258.00 | +2.67% | 137,357 |
| 26-10-13 | €251.30 | -0.67% | 117,965 |
| 26-10-12 | €253.00 | 0.00% | 66,745 |
| 26-10-09 | €253.00 | +2.47% | 81,091 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- SRT3 Stock
Select your edition
All financial news and data tailored to specific country editions
